Navigation Links
Actavis Plans Latin America Expansion

SUNRISE, Fla., Oct. 5, 2011 /PRNewswire/ -- Actavis Group CEO Claudio Albrecht today announced a major sales expansion into Latin America, among the world's fastest-growing markets for generic drugs.

Albrecht outlined the company's growth strategy at a meeting in South Florida with Actavis' new Latin American business unit. The Latin America team, based in Sunrise, Florida, will target Brazil, Argentina, Colombia, Mexico, Venezuela and other key markets in the region.  

With generic drugs not as widely used in South and Central America as in the United States and Europe, Albrecht said that Actavis' portfolio of nearly 900 lower-cost alternatives to brand medications represents a potential healthcare solution for millions. "This is not only a tremendous opportunity for Actavis to grow as a company, but also to bring great value to consumers while supporting better health," he said.

According to IMS Health, generic sales in Latin America grew by 14 percent from 2009 to 2010, compared to 4.4 percent worldwide. Generic sales in Latin America totalled $53.4 billion last year. Actavis Group, the world's fourth largest generic pharmaceutical company, already operates in more than 40 countries, and plans another major expansion in Japan.

The Latin America unit, headed by Ricardo Quirch, also includes specialists in regulatory affairs, portfolio and business development, supply-chain management and business administration. Quirch joined Actavis from Sandoz, the generics division of Novartis, most recently leading cross-divisional Asia-Pacific sourcing for the company.

"The decisions we are making now will have long-term benefits for health consumers in these countries," said Quirch. "We began with two products that we acquired several years ago and are now reviewing more than 20 products to potentially add to our portfolio, and in the process of receiving regulatory approval to begin marketing others."      

The Latin America unit is part of Actavis Inc., the global company's New Jersey-based U.S. subsidiary headed by U.S. CEO Doug Boothe.

About Actavis Inc.
Actavis Inc. is the U.S. subsidiary of Actavis Group hf. Approximately one third of Actavis' sales are generated in North America, Actavis' single largest market. Based in Morristown, NJ, Actavis has U.S. manufacturing and packaging facilities in Elizabeth, NJ; a manufacturing facility in Lincolnton, NC; research and development facilities in Owings Mills, MD and Sunrise, FL.; and a commercial development office in Sunrise, FL. Please visit for more information.

About Actavis Group
Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. The company has operations in 40 countries, with more than 10,500 employees. Please visit for more information.

SOURCE Actavis
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Actavis Launches Generic Keppra XR® Tablets in the U.S.
2. Avanir Pharmaceuticals Files Lawsuits Against Par and Actavis for Infringement of NUEDEXTA Patents
3. Actavis Launches Oxymorphone Hydrochloride Extended-Release Tablets, CII in the U.S.
4. Actavis Hails U.S. Supreme Court Decision in Labeling Cases
5. Actavis Receives FDA Approval of Zolpidem Tartrate Extended-Release Tablets USP, 12.5 mg CIV in the U.S.
6. Actavis Receives FDA Approval of Donepezil Hydrochloride Tablets in the U.S.
7. Actavis Receives Approval of Valacyclovir Hydrochloride Tablets in the U.S.
8. Actavis Receives Approval of Pantoprazole Sodium Delayed-Release Tablets, USP in the U.S.
9. Actavis Encourages Consumers to Return Fentanyl Transdermal System 25 mcg/h
10. Actavis Inc. Issues a Voluntary Recall of 18 Lots of Fentanyl Transdermal System 25 mcg/h
11. Actavis Receives Approval of Zolpidem Tartrate Extended-Release Tablets, USP 6.25mg CIV in the U.S. with 180-Day Marketing Exclusivity
Post Your Comments:
(Date:11/25/2015)... 2015 Research and Markets ( ) ... - Global Forecast to 2020" report to their ... for 37.21% of the total market share in 2014. ... region is projected to growth at the highest CAGR ... primarily to the fast growing water, industrial gas treatment, ...
(Date:11/24/2015)... 25, 2015 WuXi PharmaTech (Cayman) Inc. ("WuXi" ... open-access R&D capability and technology platform company serving the ... China and the ... extraordinary general meeting of shareholders held today, the Company,s ... and approve the previously announced agreement and plan of ...
(Date:11/24/2015)... N.C. , Nov. 24, 2015  In the ... projects in an effort to quickly uncover new insights, ... --> --> However, ... a market research project and ensure that all rules ... and industry standards. Another major barrier to efficiently launching ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... , ... Beddit® has launched a new Android app for use ... a more intuitive SleepScore™ that rates sleep quality on a 100-point scale and makes ... by a proprietary algorithm. Beddit analyzes the data to provide an easy to understand ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... provide scholarships for people struggling with eating disorders as a result of the ... second annual event, held at Fox Run Golf Club in Eureka, will help ...
(Date:11/25/2015)... ... 2015 , ... Many people know of the common symptoms of low thyroid ... skin. But many people who find their cholesterol levels and weight are creeping up ... especially if they don’t have any of the other symptoms. , Thyroid hormone plays ...
(Date:11/24/2015)... ... 2015 , ... Genesis Chiropractic Software helps practice owners automate ... between the practice owner and the patient that automatically manages all five aspects ... Click here to learn more. , According to Dr. Brian ...
(Date:11/24/2015)... Dallas, Texas (PRWEB) , ... November 24, 2015 , ... ... of all charitable donations are made in the last five weeks of the year ... #GivingTuesday was created in 2012 to connect the nation’s charities with those individuals who ...
Breaking Medicine News(10 mins):